Singapore, July 8 -- RoosterBio and Qkine have entered a distribution agreement to provide U.S. customers with a single-source platform for cells, bioprocess media and recombinant growth factors.

The partnership gives advanced therapy developers access to RoosterBio's cellular starting materials, engineered bioprocess media and exosome production solutions, alongside Qkine's high-purity, animal-origin-free recombinant growth factors, cytokines and bioactive proteins.

This is relevant because cell therapy, exosome therapy and regenerative medicine developers rely on complex raw materials that can affect product quality, potency, manufacturability and cost of goods. Fragmented sourcing can slow development and create variability when prog...